A bidding war for 23andMe culminated with former CEO Anne Wojcicki’s nonprofit, TTAM Research Institute, winning the auction with a $305 million offer that surpasses Regeneron’s $256 million bid. The deal includes company assets such as Personal Genome Service and research businesses, with commitments to privacy policies protecting consumer genetic data. The bankruptcy court will review the sale to ensure protections and ongoing use of de-identified data for academic research.